Cardiff Oncology Inc Revenue per Employee (CRDF), current and historic results, rankings and more, quarterly fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Cardiff Oncology Inc   (NASDAQ: CRDF)
 

Cardiff Oncology Inc 's Revenue per Employee

Quarterly Results, Trends, Rankings, Statistics, Cumulative Sales


Cardiff Oncology Inc 's Revenue per employee fell on a trailing twelve month basis to $ 16,387, below the company average number of $24,400.
Within the Healthcare sector Employees of 539 other companies have achieved higher revenue per employee. While revenue/employee total ranking has improved so far to 3590, from total ranking in previous quarter at 4083. Cardiff Oncology Inc has 31 employees.


What is Sales per Employee Ratio?






Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CRDF Revenue per Employee (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Revenue Change -14.05 % -62.39 % 62 % -27.27 % -25.77 %
Sales per Employee (TTM) $ 16,387 16,935 19,129 16,129 17,581
CRDF's Total Ranking # 3590 # 4083 # 3760 # 3825 # 3809
Seq. Revenue Change 153.66 % -83.13 % 102.5 % -0.83 % 11.01 %

CRDF Company Profile >> Back to CRDF Efficiency Comparisons >> Compare CRDF Sales per Employee to its Competitors

Revenue per Employee Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 67
Healthcare Sector # 540
Overall Market # 3590

Revenue per Employee Statistics
High Average Low
$ 117,968 $ 24,400 $ 1,765
(Mar 31 2024)   (Jun 30 2020)



Financial Statements
Cardiff Oncology Inc 's Revenue MRQ $ 0 Millions Visit CRDF's Income Statement
Cardiff Oncology Inc 's Revenues TTM $ 1 Millions Visit CRDF's aggregate revenue growth
What are CRDF's Sales? Visit CRDF's Sales by Segment


  News about Cardiff Oncology Inc Revenue per employee

Cardiff Oncologys Breakthrough in RAS-mutated mCRC Trial Amidst Revenue Setbacks

The landscape of drug development for metastatic colorectal cancer (mCRC) is ever-evolving, with a focus on targeted therapies that can improve patient outcomes. Cardiff Oncology Inc. recently announced positive initial data from their Phase 2 CRDF-004 clinical trial, which is evaluating the combination of onvansertib with standard care for first-line treatment in RAS-mutated mCRC patients. These promising clinical results come at a time when the company faces significant financial and competitive challenges, highlighting the complex interplay between clinical success and business growth in the biotech industry. Clinical Trial Insights Cardiff Oncology s CRDF-004 trial marks a significant step forward in the battle against RAS-mutated mCRC. The preliminary data reveals an impressive 64% response rate (ORR) in patients treated with a 30mg dose of onvansertib, compared to a 33% ORR in the control group receiving only the standard of care. This data signals a potential breakthrough, suggesting that onvansertib, as part of a combination therapy, could offer a substantial enhancement over existing treatment options for this hard-to-treat cancer subtype.



Other Ratios
Cardiff Oncology Inc 's Income per Employee
Employees in Biotechnology & Pharmaceuticals
Biotechnology & Pharmaceuticals Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
CRDF's Revenue per Employee versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for CRDF's Competitors
Revenue per Employee for CRDF's Suppliers
Revenue per Employee for CRDF's Customers

You may also want to know
CRDF's Sales Growth Rates CRDF's Pe Price to earnings ratio CRDF's Receivables Turnover Ratio CRDF's Stock Quote
CRDF's Net Income Growth Rates CRDF's Ps Price to Sales ratio CRDF's Sales per Employee CRDF's Asset Turnover Ratio
CRDF's Net Margin CRDF's Pb Price to Book ratio CRDF's Financial Strength Ratios CRDF's Dividend Payout Ratio
Date modified: 2026-09-03T11:39:45+00:00




Companies with similar Revenue per Employee for 12 months ending Jun 30 2026, within Healthcare Sector Revenue per Employee Revenue 12 months ending Jun 30 2026Number of Employees Jun 30 2026
Scientific Industries Inc   28,357.43 $ 5.728  Million 202 
Nexalin Technology Inc   27,144.38 $ 0.217  Million 8 
Bioxcel Therapeutics Inc   25,586.21 $ 0.742  Million 29 
Bioadaptives Inc   25,561.00 $ 0.026  Million 1 
Ataibeckley Inc   22,143.56 $ 4.473  Million 202 
Envoy Medical Inc   20,700.00 $ 0.207  Million 10 
Northwest Biotherapeutics Inc  20,695.24 $ 2.173  Million 105 
China Pharma Holdings Inc  17,710.83 $ 3.914  Million 221 
Cardiff Oncology Inc   16,387.10 $ 0.508  Million 31 
Mangoceuticals Inc   14,328.50 $ 0.315  Million 22 
Absci Corp  11,150.00 $ 1.561  Million 140 
Skinvisible Inc   10,000.00 $ 0.020  Million 2 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.